CVS Turnaround Progresses, But Valuations No Longer a Bargain

What happened

CVS Health has executed a significant turnaround under new management, with operational improvements driving a doubling of the share price since early 2025. Debt leverage is declining, cash flow is robust, and the Health Care Benefits segment's margin rebounded to 8.5% in Q1 2026. The DeepValue report confirms solid fundamentals, with raised 2025 adjusted EPS guidance and a >$500M restructuring program on track. However, the stock's price appreciation has compressed the margin of safety, and it no longer trades at the bargain levels seen previously. Despite projected 10–15% annual EPS growth, near-term upside may be limited as the market prices in the improvements.

Implication

The thesis remains intact, but the risk/reward is less compelling. Execution on PBM transparency and Medicare margins is key. If the stock corrects, it becomes a strong buy again. Otherwise, long-term holders can maintain positions, but new money may find better entry points.

Thesis delta

The valuation is now more aligned with fundamentals, reducing the previously attractive margin of safety. While the turnaround continues to execute, the stock's price appreciation means the risk/reward is no longer as skewed in favor of investors. Future upside relies more on sustained EPS growth and multiple expansion, which require flawless execution.